Search results for: Precision Medicine
Filter search results
Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
15 September 2021
…market. Despite H.R. 3’s unprecedented impact on the world’s largest pharmaceutical market, the CBO model projected that only 8 fewer new medicines (as measured by the number of New Molecular…
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
…do not employ HTA processes. Health interventions and technologies to be included in the UCS undergo three separate processes: (i) the National List of Essential Medicines (NLEM), (ii) the Universal…
NICE’s severity modifier: a step in the right direction, but still a long way to go
23 March 2022
…medicine being appraised is for a severe disease, which in some cases means that a higher cost-effectiveness threshold (or quality-adjusted life year [QALY] weighting) may be formally applied. NICE essentially…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
…on Health. Available from https://www.ohe.org/publications/tuberculosis. Kettler, H. and Towse, A. (2002) Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty. OHE Monograph. Available from https://www.ohe.org/publications/public-private-partnerships-research-and-development-medicines-and-vaccines-diseases…
OHE Welcomes Patrick Holmes to the Board of Trustees
28 March 2022
…expert on developing global policy initiatives to drive affordable patient access to innovative medicines which is core to OHE’s mission.” Patrick Holmes is an industry veteran with over 30 years…
OHE Innovation Policy Prize
18 May 2022
…delivers for each and every one of us. The record-breaking development of multiple COVID-19 vaccines, potential curative gene therapies for spinal muscular atrophy, or even the antibiotics which enables medicine…
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
7 January 2020
The National Institute of Health and Care Excellence (NICE) makes recommendations for the use of interventions including medicines in the National Health Service in England based on their clinical and…
Real Option Value and Path Dependence in Oncology Innovation
1 April 2014
Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available…
New Frontiers in Health
7 January 1964
A review of the incidence, impact and implications of minor and unrecognised illness in the community This booklet is about the future of medicine. It presents information about the many…